5AM Venture Management, LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), 5AM Venture Management, LLC reported 26 stock positions worth $446.6 million. Its top holding was Enliven Therapeutics (ELVN) at 15.1% of the portfolio, followed by Entrada Therapeutics (TRDA, 14.0%) and Dianthus Therapeutics (DNTH, 8.3%). Compared with Q4 2023, it opened 5 new positions, sold out of 4, added to 4 and reduced 5. The biggest buy was a new position in Praxis Precision Medicines I (PRAX) and the biggest sale an exit from Disc Medicine (IRON).
- Most Recent 13F
- Q2 2026
- Location
- SAN FRANCISCO, CA
- CIK
- 0001799883
- Portfolio Value
- $446.6M (Q1 2024)
- SEC Filing
- 0001104659-24-061973 ↗ filed May 15, 2024
Holdings Value
Holdings 26 stocks · $446.6M
| ELVN Enliven Therapeutics Inc. | 15.11% | 3,835,975 | $67.5M | Reduce -25.7% |
| TRDA Entrada Therapeutics Inc. | 13.99% | 4,408,379 | $62.5M | No change |
| DNTH Dianthus Therapeutics Inc. | 8.34% | 1,242,029 | $37.3M | Reduce -15.6% |
| MRUS Merus NV | 5.53% | 548,825 | $24.7M | Add +5.2% |
| CLDX Celldex Therapeutics Inc. | 4.67% | 497,270 | $20.9M | No change |
| PRAX Praxis Precision Medicines I | 4.65% | 340,000 | $20.7M | New |
| VKTX Viking Therapeutics Inc. | 4.36% | 237,560 | $19.5M | Reduce -59.4% |
| PHVS Pharvaris NV | 4.13% | 797,600 | $18.4M | No change |
| BHVN Biohaven Ltd. | 3.92% | 319,972 | $17.5M | Reduce -20.0% |
| RNAM Avidity Biosciences Inc. | 3.80% | 665,555 | $17.0M | No change |
| TYRA Tyra Biosciences Inc. | 3.45% | 939,298 | $15.4M | Add +69.3% |
| VOR Vor Biopharma Inc. | 3.38% | 6,361,723 | $15.1M | No change |
| MLTX Moonlake Immunotherapeutics | 3.17% | 282,313 | $14.2M | Reduce -6.7% |
| CNTA Centessa Pharmaceuticals Ltd. | 3.15% | 1,245,000 | $14.1M | New |
| VRDN Viridian Therapeutics Inc. | 2.89% | 736,595 | $12.9M | Add +25.6% |
| SLN Silence Therapeutics PLC-ADR | 2.30% | 476,200 | $10.3M | New |
| ANAB Anaptysbio Inc. | 1.80% | 357,733 | $8.1M | No change |
| ZNTL Zentalis Pharmaceuticals Inc. | 1.73% | 490,000 | $7.7M | No change |
| ADVM Adverum Biotechnologies Inc. | 1.71% | 541,666 | $7.7M | New |
| RLYB Rallybio Corp. | 1.50% | 3,630,724 | $6.7M | No change |
| GHRS GH Research PLC | 1.37% | 572,665 | $6.1M | Add +41.6% |
| SCPH Scpharmaceuticals Inc. | 1.35% | 1,200,647 | $6.0M | No change |
| MERSANA THERAPEUTICS INC | 1.31% | 1,305,000 | $5.8M | No change |
| COGT Cogent Biosciences Inc. | 1.19% | 790,440 | $5.3M | No change |
| QTTB Q32 Bio Inc. | 0.96% | 251,994 | $4.3M | New |
| CIDARA THERAPEUTICS INC COM NEW | 0.23% | 1,134,511 | $1.0M | No change |
Portfolio Sells Q4 2023 → Q1 2024
| IRON Disc Medicine Inc. | Sold out | 0.00% | −4.51 |
| ELVN Enliven Therapeutics Inc. | Reduce -25.7% | 15.11% | −3.84 |
| MRTX Mirati Therapeutics Inc. | Sold out | 0.00% | −3.00 |
| SPRB Spruce Biosciences Inc. | Sold out | 0.00% | −1.84 |
| MLTX Moonlake Immunotherapeutics | Reduce -6.7% | 3.17% | −1.67 |
| HOMOLOGY MEDICINES INC | Sold out | 0.00% | −0.73 |
| BHVN Biohaven Ltd. | Reduce -20.0% | 3.92% | −0.62 |
| VKTX Viking Therapeutics Inc. | Reduce -59.4% | 4.36% | +1.47 |
| DNTH Dianthus Therapeutics Inc. | Reduce -15.6% | 8.34% | +4.28 |
Portfolio Buys Q4 2023 → Q1 2024
| PRAX Praxis Precision Medicines I | New | 4.65% | +4.65 |
| CNTA Centessa Pharmaceuticals Ltd. | New | 3.15% | +3.15 |
| SLN Silence Therapeutics PLC-ADR | New | 2.30% | +2.30 |
| MRUS Merus NV | Add +5.2% | 5.53% | +1.73 |
| ADVM Adverum Biotechnologies Inc. | New | 1.71% | +1.71 |
| TYRA Tyra Biosciences Inc. | Add +69.3% | 3.45% | +1.41 |
| QTTB Q32 Bio Inc. | New | 0.96% | +0.96 |
| GHRS GH Research PLC | Add +41.6% | 1.37% | +0.74 |
| VRDN Viridian Therapeutics Inc. | Add +25.6% | 2.89% | −0.50 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 16 | $287.9M | MPLT, TYRA, TRDA, PHVS, CAMP |
| Q1 2026 | 20 | $360.2M | ERAS, TRDA, TYRA, CAMP, CNTA |
| Q4 2025 | 21 | $318.1M | TRDA, CAMP, TYRA, VRDN, PHVS |
| Q3 2025 | 25 | $273.0M | SKYE, TRDA, PHVS, CAMP, CNTA |
| Q2 2025 | 29 | $260.1M | SKYE, TRDA, DNTH, ELVN, PHVS |
| Q1 2025 | 31 | $264.4M | TRDA, ELVN, DNTH, SKYE, PHVS |
| Q4 2024 | 31 | $419.1M | TRDA, ELVN, SKYE, TECX, ARTV |
| Q3 2024 | 28 | $484.0M | TRDA, ELVN, SKYE, ARTV, DNTH |
| Q2 2024 | 28 | $447.1M | SKYE, TRDA, ELVN, DNTH, CLDX |
| Q1 2024 | 26 | $446.6M | ELVN, TRDA, DNTH, MRUS, CLDX |